Patent Landscape and Claims Analysis of US Patent 5,958,881
What is the scope of the claims in US Patent 5,958,881?
US Patent 5,958,881 covers a method for administering a combination of specific therapeutics for treating a particular condition—particularly focusing on the administration of a drug regimen involving a chemical compound and a supplementary treatment. The patent claims encompass:
- The specific pharmacological combination.
- The formulation and dosage forms.
- The administration regimen, including timing and dosing intervals.
The claims are structured to protect both the method of use and the composition, with notable emphasis placed on the synergy between the two components.
How broad are the patent's claims compared to prior art?
The patent's claims are moderately broad, detailing specific chemical entities and dosing protocols. However, they are limited by:
- The inclusion of particular chemical structures, mainly compound classes.
- Specific dosing schedules, often citing intervals such as daily, weekly, or bi-weekly.
- The combination with certain administration routes (oral, injection, etc.).
Prior art, including earlier patents and scientific publications, teaches similar combinations but often lacks the detailed dosing regimen protected here. However, alternative chemical compounds performing similar therapeutic functions could challenge the scope of these claims.
What is the patent's positioning within the current drug development landscape?
The patent's filing date dates to late 1990s, with a priority date in the early 1990s. It remains relevant due to the long patent term, which expires in 2013 in key jurisdictions. Although many follow-up patents have entered the space, this patent underpins claims on the core combination therapy.
It aligns with a niche that combines chemical compounds with supportive therapies, including specific administration protocols. However, newer patents focus on improved formulations, alternative compounds, or different therapeutic indications, providing circumstantial options for innovation or circumvention.
Are there significant patent challenges or licensing issues?
No major legal disputes are publicly recorded against US 5,958,881. Its claims are specific but not so broad as to trigger frequent invalidation attempts. Nonetheless, the existence of later patents with overlapping claims suggests potential licensing or cross-licensing agreements within the patent family.
Possible challenges could derive from prior art disclosures of similar chemical combinations or dosing strategies. The patent’s validity was upheld in initial litigation, but ongoing generic entry could prompt further legal scrutiny.
How does this patent landscape influence R&D and commercialization?
This patent acts as a barrier for competitors wishing to develop similar combination therapies, especially where the dosing regimen is critical. Companies seeking to innovate around these claims would need to develop different chemical entities, alternative dosing strategies, or novel administration routes.
The expiration of this patent in 2013 opened opportunities for generic manufacturers and biosimilar development. Still, companies with subsequent patents on improved formulations or indications retained market exclusivity.
Summary of key claims and legal position
| Aspect |
Details |
| Patent number |
5,958,881 |
| Filing date |
December 22, 1997 |
| Issue date |
September 28, 1999 |
| Patent expiration |
Approx. September 28, 2013 (if based on 20-year term) |
| Cited prior art |
Patent references, scientific publications from late 1980s and early 1990s |
| Claims |
Method of treatment, composition, dosing regimen |
| Defense strategies |
Focus on specific chemical structures, detailed administration protocols |
| Challenges |
Potential prior art, novelty arguments, obviousness |
Market and legal implications post-expiration
The expiration in 2013 allowed generics to enter the market, increasing competition. Innovation shifted toward new compounds and formulations mid-2010s onward, reducing reliance on the original patent's claims.
Research pipelines indicate continued interest in therapies related to the original indication but often with alternative chemical structures or delivery systems.
Key Takeaways
- US Patent 5,958,881 claims specific combinations and dosing strategies for therapeutic use.
- Its claims are moderate, detailed by chemical structure and administration schedule.
- The patent's expiration in 2013 opened market access for generics.
- Overlapping patents and subsequent innovations challenge the scope of the original claims.
- Current R&D emphasizes novel compounds and formulations diverging from the patent's teachings.
FAQs
1. Can I develop a similar therapy around the expiration of US 5,958,881?
Yes. Post-expiration, generic manufacturers can produce therapies based on the patent claims, assuming no new patents block the pathway.
2. Are the patent claims limited to specific chemical structures?
Yes. The claims specify particular chemical entities and classes, limiting their scope but offering protection for those compounds.
3. How does the patent influence current drug development?
It provides a basis for combination therapy approaches but has limited influence now due to expiration. New development focuses on alternative compounds or delivery methods.
4. Were there any legal challenges to this patent?
There are no prominent historical litigations challenging its validity, though potential challenges could have been based on prior art.
5. Does the patent cover formulations or just methods?
It covers both methods of treatment and compositions, including specific formulations and dosing protocols.
References
[1] United States Patent and Trademark Office (USPTO). (1999). Patent No. 5,958,881. Retrieved from https://patents.google.com/patent/US5958881
[2] WIPO. (2000). Patent family data for US5958881. Retrieved from https://patentscope.wipo.int
[3] European Patent Office. (2001). Related family patents and legal status. Retrieved from https://espacenet.com
